Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Medicine (Baltimore) ; 100(22): e26253, 2021 Jun 04.
Article in English | MEDLINE | ID: covidwho-1258821


ABSTRACT: Pathophysiological changes are important risk factors for critically ill patients with pneumonia manifesting sub-therapeutic antibiotic exposures during empirical treatment. The effect of coronavirus disease 2019 (COVID-19) on antibiotic dosing requirements is uncertain. We aimed to determine the effect of COVID-19 on ß-lactam pharmacokinetics (PK) and PK target attainment in critically ill patients with a personalized dosing strategy.Retrospective, single-center analysis of COVID-19 ± critically ill patients with pneumonia (community-acquired pneumonia or hospital-acquired pneumonia) who received continuous infusion of a ß-lactam antibiotic with dosing personalized through dosing software and therapeutic drug monitoring. A therapeutic exposure was defined as serum concentration between (css) 4 to 8 times the EUCAST non-species related breakpoint).Data from 58 patients with pneumonia was analyzed. Nineteen patients were tested COVID-19-positive before the start of the antibiotic therapy for community-acquired pneumonia or hospital-acquired pneumonia. Therapeutic exposure was achieved in 71% of COVID-19 patients (68% considering all patients). All patients demonstrated css above the non-species-related breakpoint. Twenty percent exceeded css above the target range (24% of all patients). The median ß-lactam clearance was 49% compared to ß-lactam clearance in a standard patient without a significant difference regarding antibiotic, time of sampling or present COVID-19 infection. Median daily doses were 50% lower compared to standard bolus dosing.COVID-19 did not significantly affect ß-lactam pharmacokinetics in critically ill patients. Personalized ß-lactam dosing strategies were safe in critically ill patients and lead to high PK target attainment with less resources.

COVID-19/drug therapy , beta-Lactams/administration & dosage , beta-Lactams/pharmacokinetics , Aged , Aged, 80 and over , Body Mass Index , Critical Illness , Dose-Response Relationship, Drug , Drug Monitoring , Female , Humans , Infusions, Intravenous , Male , Metabolic Clearance Rate , Middle Aged , Retrospective Studies , SARS-CoV-2 , Severity of Illness Index , beta-Lactams/economics , beta-Lactams/therapeutic use